Bio-Amd Inc (BIAD) 0.0260 $BIAD Bio-AMD, Inc.

New Post Public Reply Private Reply Replies (0) Message Board

Jul 7, 2016 at 2:05 PM

Bio-Amd Inc (BIAD) 0.0260 $BIAD

Bio-AMD, Inc. Restructuring, MIDS Project Commences
Marketwired - Tue Jun 21, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - Jun 21, 2016) - Bio-AMD, Inc. and Bio-AMD UK Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"

(OTCQB: BIAD) here provides an update on our MIDS project and a restructuring of our medical device subsidiary operations.

Bio-AMD, Inc.; COAG PT/INR Point of Care Hemostasis Project & Patent Update
Marketwire Canada - Thu May 12, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - May 12, 2016) - Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"

(OTCQB: BIAD) here provides an update on its PT/INR COAG project and on other matters around its business.

Bio-AMD, Inc.: MIDS Patent Grant in People's Republic of China
Marketwired - Thu Mar 03, 7:30AM CST
Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"

(OTCQB: BIAD) is pleased to confirm that it has received a Certificate of Grant of a patent in the People's Republic of China ("PRC"

for our Magnetic Immunoassay Detection System (MIDS) technology platform.

Bio-AMD, Inc.: First MIDS Patent Grant Likely, Shareholder Update
ACCESSWIRE - Mon Jan 11, 7:30AM CST
DARESBURY, ENGLAND / ACCESSWIRE / January 11, 2016 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to provide an update on progress for shareholders.

Bio-AMD, Inc.; United States Patent Granted for PT/INR Technology
ACCESSWIRE - Thu Jul 16, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / July 16, 2015 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"

(OTCQB: BIAD), is pleased to announce that it has recently received formal notice of a grant of a United States Patent ("Grant"

for its Low Volume Assay Apparatus used in its point of care system for the measurement of Prothrombin Time / International Normalized Ratio ("PT/INR"

.

Bio-AMD, Inc.; Ethics Approval for Patient Testing Study
ACCESSWIRE - Thu Jul 02, 7:45AM CDT
LONDON, ENGLAND, UK /ACCESSWIRE / July 2, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"

(OTCQB: BIAD), is pleased to announce it has obtained a "favourable ethical opinion" from the North West Centre of Research Ethics Committees of the UK's National Research Ethics Service (together, "NRES"

, enabling it to undertake sample testing from patients as part of its development program.

Bio-AMD, Inc.; MIDS Proof of Market Report
ACCESSWIRE - Mon Jun 01, 7:37AM CDT
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"

(OTCQB: BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report"

, part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS"

technology.

Bio-AMD, Inc.; Implementation of ISO9001 and ISO 13485 Quality Standards
ACCESSWIRE - Thu May 21, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / May 21, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to announce that it is to formalise implementation of the International Organisation for Standardization quality standards ISO 9001:2008 and ISO 13485:2012.

Bio-AMD, Inc.; Grant Funded Technical Support from the University of Liverpool
ACCESSWIRE - Tue May 05, 7:45AM CDT
LONDON, ENGLAND /ACCESSWIRE / May 5, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"

(OTCQB: BIAD), is pleased to announce that it has recently received grant funded assistance from the University of Liverpool to assist in the further development of its micro-fluidic technology, especially in relation to our proposed Magnetic Immunoassay Detection System ("MIDS"

program.

Bio-AMD, Inc.; General Update and MIDS Plans
eTeligis - Tue Apr 14, 12:11AM CDT
LONDON, ENGLAND, United States, via ETELIGIS INC., 03/31/2015 - - Bio-AMD, Inc. (OTCQB: BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"

provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015.

Bio-AMD, Inc.; General Update & MIDS Plans
ACCESSWIRE - Tue Mar 31, 7:31AM CDT
LONDON, ENGLAND / ACCESSWIRE / March 31, 2015 / Bio-AMD, Inc. (OTCQB:BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"

provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015.

Bio-AMD, Inc. Agreement with Sysmex & General Update
ACCESSWIRE - Tue Jan 27, 7:46AM CST
LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"

(OTCQB: BIAD) provides an update on the Company's plans for 2015.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bob Evans' Protein Mac & Cheese: Practical Power Play

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Charter Next Generation Unveils Gen 2 MDO-PE Films

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Karoo Health Leaps Forward with New CCO Breton

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Epic Political Thriller Explores Humanity's Future

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

JiMMYBAR! Expands Creatine Market with Target Launch

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...